GlassScriptPhysician profile
Ann Monardo
NPI 1053832311
$8,203.96
in general payments reported to CMS, 2019-2025
34 companies · $2,142 in 2025
The $2,142 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $404 · 2021: $413 · 2022: $1,727 · 2023: $1,389 · 2024: $1,856 · 2025: $2,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,352 · Education: $34.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,352.45 |
| Education | $34.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,233.08 | 2019-2025 | |
| Janssen Biotech, INC. | $1,065.42 | 2020-2025 | Stelara, Tremfya, Remicade |
| Regeneron Healthcare Solutions, INC. | $619.62 | 2022-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $549.51 | 2022-2025 | Xifaxan, Trulance |
| Janssen Scientific Affairs, LLC | $422.87 | 2021-2023 | Stelara |
| Gilead Sciences, INC. | $339.71 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $328.98 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Ambu INC. | $260.49 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $237.09 | 2021-2023 | Zeposia |
| Ardelyx, INC. | $233.49 | 2023-2025 | Ibsrela |
| Qol Medical, LLC | $228.83 | 2023-2025 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $193.62 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $182.47 | 2024-2025 | Voquezna |
| Genzyme Corporation | $151.97 | 2023-2025 | |
| Cook Medical LLC | $151.47 | 2020-2023 | Fusion |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $147.11 | 2022 | |
| Lilly USA, LLC | $124.75 | 2023-2025 | Omvoh |
| Madrigal Pharmaceuticals | $118.92 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $98.32 | 2023-2024 | Linzess |
| Medtronic, INC. | $96.49 | 2023-2024 | Endoflip |
| Pfizer INC. | $78.60 | 2025 | |
| Aimmune Therapeutics, INC. | $76.50 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $50.28 | 2019-2023 | Andexxa |
| Braintree Laboratories, INC. | $35.14 | 2025 | Suflave |
| Celgene Corporation | $30.26 | 2023 | Zeposia |
| Organon LLC | $25.01 | 2024 | |
| Novo Nordisk INC | $21.66 | 2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $20.71 | 2024 | Givlaari |
| Olympus America INC. | $15.53 | 2022 | |
| Amgen INC. | $14.19 | 2023 | Amjevita, Avsola |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.47 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $13.46 | 2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $13.30 | 2023 | Dificid |
| Boston Scientific Corporation | $11.64 | 2025 | Axonics |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Monardo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.